Liu X, et al. – The authors wished to clarify the link between the early presence of common adverse events (AEs) and clinical outcomes in metastatic gastric cancer (GC) patients. This retrospective cohort study suggested that presence of hypertension (HTN), proteinuria, or hand and foot syndrome (HFS) during the first cycle of apatinib treatment was a viable biomarker of antitumor efficacy in metastatic GC patients.